Overview

A Study of Bermekimab in Patients With Hidradenitis Suppurativa

Status:
Completed
Trial end date:
2019-01-14
Target enrollment:
Participant gender:
Summary
Phase 2 study of bermekimab in patients with moderate to severe Hidradenitis Suppurativa.
Phase:
Phase 2
Details
Lead Sponsor:
Janssen Research & Development, LLC
XBiotech, Inc.
Treatments:
Antibodies
Antibodies, Monoclonal